Reuters logo
BRIEF-Acadia Pharmaceuticals initiates phase III study of Pimavanserin
October 4, 2017 / 8:23 PM / 2 months ago

BRIEF-Acadia Pharmaceuticals initiates phase III study of Pimavanserin

Oct 4 (Reuters) - Acadia Pharmaceuticals Inc

* Acadia Pharmaceuticals initiates phase III study of Pimavanserin in dementia-related psychosis

* FDA grants breakthrough therapy designation to Pimavanserin for dementia-related psychosis​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below